Edifecs Tops Best in KLAS for CMS Payer Interoperability Category for the Second Year in a Row

Edifecs interoperability solutions enable compliance with CMS Interoperability and Prior Authorization Final Rule

Edifects

Edifecs, Inc., a global health information technology solutions company, announced today that the Edifecs interoperability platform, XEngine Server for FHIR® and EDI, has been named the market leader for CMS Payer Interoperability for the second consecutive year by KLAS Research in its 2024 Best in KLAS: Software & Services report. Edifecs was ranked as the leader among vendors that provide software designed to meet the requirements for CMS-related payer and state agencies by providing patient access API, provider directory API, and payer-to-payer data exchange. Edifecs topped the list with a score of 92.2, surpassing its own market-leading score of 87.9 in 2023.

Industry Leader

With nearly three decades of experience innovating at scale, Edifecs is the industry leader in helping hundreds of healthcare organizations achieve ongoing interoperability and compliance. Edifecs’ KLAS-award winning interoperability platform now includes the FHIR API for Prior Authorization and EDI capability required to address all components of the CMS-0057-F mandate. The solution is already available to multiple Edifecs customers, giving them a competitive head start on compliance well in advance of the 2026/2027 deadlines.

Best in KLAS Award

The Best in KLAS award furthers Edifecs’ recognition as the market standard for administrative, clinical, and pharmacy interoperability. Additionally, Edifecs is a CMS approved vendor for verifying industry data via its administrative simplification testing tool and the vendor of choice for CAQH for industry operating rules certification.

Venkat Kavarthapu, CEO, Edifecs

“We are honored to be recognized by KLAS for the second year in a row in the CMS Payer Interoperability category. Since our inception, Edifecs has been focused on harnessing data—making sure the data is accessible and accurate, distilling meaning from that data, and ensuring it can be shared and applied when and where it is needed. This deep knowledge makes our platform the proven choice to future-proof capabilities and ease the adoption of new compliance mandates like CMS-0057-F. Our solutions are designed to help successfully manage complexity, increase the ROI of existing core systems, and replace the pervasive friction between payers, providers, and members with collaboration and transparency, enabling the successful adoption of value-based programs. This KLAS award validates our work to catalyze interoperability across the healthcare system.”

Unified Interoperability Solution

Edifecs is uniquely positioned to provide a unified interoperability solution that enables the exchange of any kind of data between partners. Its solution is the gold standard because of its completeness, the richness of its functionality, and the level of support the organization offers. This is a significant differentiator and a major contributor to Edifecs being awarded Best in KLAS for the second year in a row. The Edifecs interoperability platform enables the exchange, unification, and processing of all data including proprietary flat files, healthcare administrative transaction files, pharmacy data, clinical data, and unstructured data. With the Edifecs Cloud, customers are able to increase the ROI of existing IT systems and avoid the costly and disruptive “rip and replace” alternative.

Adam Gale, CEO, KLAS Research

“At KLAS, we firmly believe that the voice of healthcare providers and payers is paramount. The Best in KLAS awards are based on extensive feedback and evaluations from healthcare professionals across the nation. Winning a Best in KLAS award, therefore, is not just about recognition; it shows the trust and confidence that healthcare providers place in the winning vendors. It also helps validate each vendor’s commitment to innovation, quality, and customer satisfaction. We are proud to recognize 2024’s Best in KLAS award winners! Their unwavering dedication to improving patient outcomes is wonderfully inspiring.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”